ATE498021T1 - Verwendung genetischer polymorphismen zur vorhersage arzneistoffinduzierter hepatotoxizität - Google Patents

Verwendung genetischer polymorphismen zur vorhersage arzneistoffinduzierter hepatotoxizität

Info

Publication number
ATE498021T1
ATE498021T1 AT04765830T AT04765830T ATE498021T1 AT E498021 T1 ATE498021 T1 AT E498021T1 AT 04765830 T AT04765830 T AT 04765830T AT 04765830 T AT04765830 T AT 04765830T AT E498021 T1 ATE498021 T1 AT E498021T1
Authority
AT
Austria
Prior art keywords
genetic polymorphisms
predicte
drug
il1a
hepatotoxicity
Prior art date
Application number
AT04765830T
Other languages
English (en)
Inventor
Karen Mccullough
Curt Wolfgang
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE498021T1 publication Critical patent/ATE498021T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/142—Toxicological screening, e.g. expression profiles which identify toxicity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT04765830T 2003-10-06 2004-10-05 Verwendung genetischer polymorphismen zur vorhersage arzneistoffinduzierter hepatotoxizität ATE498021T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50897203P 2003-10-06 2003-10-06
PCT/EP2004/011123 WO2005040415A1 (en) 2003-10-06 2004-10-05 Use of genetic polymorphisms to predict drug-induced hepatotoxicity

Publications (1)

Publication Number Publication Date
ATE498021T1 true ATE498021T1 (de) 2011-02-15

Family

ID=34520003

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04765830T ATE498021T1 (de) 2003-10-06 2004-10-05 Verwendung genetischer polymorphismen zur vorhersage arzneistoffinduzierter hepatotoxizität

Country Status (14)

Country Link
US (1) US20070248955A1 (de)
EP (1) EP1673472B1 (de)
JP (1) JP4979382B2 (de)
CN (1) CN1882705A (de)
AT (1) ATE498021T1 (de)
AU (1) AU2004283234B2 (de)
BR (1) BRPI0415299A (de)
CA (1) CA2540760C (de)
DE (1) DE602004031352D1 (de)
ES (1) ES2361018T3 (de)
MX (1) MXPA06003827A (de)
PL (1) PL1673472T3 (de)
PT (1) PT1673472E (de)
WO (1) WO2005040415A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10262107B1 (en) * 2013-03-15 2019-04-16 Bao Tran Pharmacogenetic drug interaction management system
CN108949947B (zh) * 2017-05-25 2022-06-28 上海市预防医学研究院 与抗结核药物性肝损伤发生相关的细胞色素p450基因多态性位点
CN116239665B (zh) * 2023-03-10 2024-08-23 山东大学 Ncf4在制备调控炎症小体激活的制剂中的应用和作为炎症性疾病的治疗靶点中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251598B1 (en) * 1998-10-30 2001-06-26 Interleukin Genetics, Inc. Methods for diagnosing sepsis
US6214819B1 (en) * 1998-11-23 2001-04-10 Novartis Ag Method for treating ocular neovascular diseases
AU2001294228A1 (en) * 2000-10-12 2002-04-22 Takeda Chemical Industries Ltd. Benzimidazole compounds, process for producing the same and use thereof
GB0212648D0 (en) * 2002-05-31 2002-07-10 Immunoclin Lab Ltd Treatment with cytokines

Also Published As

Publication number Publication date
PL1673472T3 (pl) 2011-07-29
EP1673472A1 (de) 2006-06-28
AU2004283234B2 (en) 2007-08-30
PT1673472E (pt) 2011-05-12
JP2007512231A (ja) 2007-05-17
CN1882705A (zh) 2006-12-20
EP1673472B1 (de) 2011-02-09
MXPA06003827A (es) 2006-06-14
DE602004031352D1 (de) 2011-03-24
CA2540760A1 (en) 2005-05-06
WO2005040415A1 (en) 2005-05-06
ES2361018T3 (es) 2011-06-13
JP4979382B2 (ja) 2012-07-18
US20070248955A1 (en) 2007-10-25
AU2004283234A1 (en) 2005-05-06
CA2540760C (en) 2013-01-08
BRPI0415299A (pt) 2006-12-26

Similar Documents

Publication Publication Date Title
FR21C1064I2 (fr) Compositions et procedes de traitement de troubles impliquant une proliferation cellulaire
ATE527385T1 (de) Mit tumoren assoziierte genetische variationen
WO2007062090A8 (en) Methods and compositions related to b cell assays
DE602005026492D1 (de) Bipolarplatte für Brennstoffzelle
EA200801046A1 (ru) Неинвазивный способ выявления переходно-клеточной карциномы мочевого пузыря in vitro
DK1721992T3 (da) Fremgangsmåder og nukleinsyrer til analyser af cellulære proliferative sygdomme
ATE539170T1 (de) Abschätzung und verringerung des risikos von graft-versus-host-reaktion
ATE408032T1 (de) Esr1 und gebärmutterhalskrebs
DE602006017365D1 (de) Zusammensetzungen für die identifizierung von adenoviren
TW200643012A (en) Pyrazolylcarboxanilides
GB201315760D0 (en) Methods and compositions of molecular profiling for disease diagnostics
IL182519A0 (en) Methods and compositions for predicting drug responses
MX378733B (es) Métodos in vitro y composiciones para identificar y usarse en el tratamiento de lupus.
MX2009013646A (es) Metodos de diagnostico y tratamiento del cancer.
AU2003285866A1 (en) Methods for assessing efficacy of chemotherapeutic agents
WO2007039290A3 (en) Methods and nucleic acids for the analysis of gene expression associated with the prognosis of cell proliferative disorders
IL200120A0 (en) Compositions, reagents and kits for and methods of diagnosing, monitoring and treating obesity and/or diabetes
MX2007007568A (es) Variantes geneticas de vkorci que predicen la sensibilidad a la warfarina.
DE602005024180D1 (de) Erzeugungssystem für brennstoffzellen des polymer-elektrolyttyps
DE60302350D1 (de) Verwendung von adenoviren mit mutationen in den va-genen für die krebstherapie
MX2008001428A (es) Compuestos de imidazolil-pirimidina para uso en el tratamiento de trastornos proliferativos.
IL166466A0 (en) Methods for the treatment of dementia based on apoe genotype
EP1987165A4 (de) Gene mit einfluss auf die menschliche gedächtnisleistung
MX2009004382A (es) Variaciones geneticas asociadas con tumores.
DE112005001317A5 (de) Polymorphismen im NOD2/Card15 Gen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1673472

Country of ref document: EP